[go: up one dir, main page]

EA200200848A1 - Способ потенцирования терапевтической эффективности таксана и его производных - Google Patents

Способ потенцирования терапевтической эффективности таксана и его производных

Info

Publication number
EA200200848A1
EA200200848A1 EA200200848A EA200200848A EA200200848A1 EA 200200848 A1 EA200200848 A1 EA 200200848A1 EA 200200848 A EA200200848 A EA 200200848A EA 200200848 A EA200200848 A EA 200200848A EA 200200848 A1 EA200200848 A1 EA 200200848A1
Authority
EA
Eurasian Patent Office
Prior art keywords
taxanes
therapeutic efficacy
taxan
potentiation
derivatives
Prior art date
Application number
EA200200848A
Other languages
English (en)
Inventor
Мариус Монсаувер
М. Дж. Роберт Ингс
Маурицио Роккетти
Original Assignee
Фармация Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А. filed Critical Фармация Италия С.П.А.
Publication of EA200200848A1 publication Critical patent/EA200200848A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Применение фосфата эстрамустина и его метаболитов эстрамустина и эстромустина позволяет потенцировать терапевтическую эффективность таксанов путем улучшения их как фармакокинетического, так и фармакодинамического профиля в результате ингибирования ферментов (CYP)2C8 и (CYP)3A4, отвечающих за метаболизм таксанов; также описаны препараты фосфата эстрамустина и метаболитов, сочетания последних с таксанами и терапевтические способы лечения с их использованием в виде сочетанной терапии.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200848A 2000-02-11 2001-02-01 Способ потенцирования терапевтической эффективности таксана и его производных EA200200848A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003201.1A GB0003201D0 (en) 2000-02-11 2000-02-11 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
PCT/EP2001/001088 WO2001058455A1 (en) 2000-02-11 2001-02-01 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof

Publications (1)

Publication Number Publication Date
EA200200848A1 true EA200200848A1 (ru) 2002-12-26

Family

ID=9885436

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200848A EA200200848A1 (ru) 2000-02-11 2001-02-01 Способ потенцирования терапевтической эффективности таксана и его производных

Country Status (16)

Country Link
US (1) US20030153539A1 (ru)
EP (1) EP1267889A1 (ru)
JP (1) JP2003524645A (ru)
KR (1) KR20020089345A (ru)
CN (1) CN1398185A (ru)
AU (1) AU3022901A (ru)
BR (1) BR0108283A (ru)
CA (1) CA2398840A1 (ru)
EA (1) EA200200848A1 (ru)
EE (1) EE200200440A (ru)
GB (1) GB0003201D0 (ru)
HK (1) HK1049967A1 (ru)
MX (1) MXPA02007677A (ru)
NZ (1) NZ521061A (ru)
WO (1) WO2001058455A1 (ru)
ZA (1) ZA200206806B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2305255T1 (sl) * 2001-12-03 2012-10-30 Bayer Healthcare Llc Arilsečninske spojine v kombinaciji z drugimi citostatičnimi ali citotoksičnimi sredstvi za zdravljenje človeških rakov
ES2369640T3 (es) 2002-05-24 2011-12-02 Angiotech International Ag Composiciones y métodos para revestir implantes médicos.
SE0203137D0 (sv) * 2002-10-24 2002-10-24 Karolinska Innovations Ab Drug target in cancer therapy
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
US7776832B2 (en) * 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69703294T2 (de) * 1996-05-22 2001-05-17 Protarga Inc., Conshohocken Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
CN1636598A (zh) * 1998-03-27 2005-07-13 法麦希亚－厄普约翰公司 加强静脉内雌莫司汀磷酸盐作用的方法
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy

Also Published As

Publication number Publication date
GB0003201D0 (en) 2000-04-05
MXPA02007677A (es) 2002-12-13
ZA200206806B (en) 2004-02-26
US20030153539A1 (en) 2003-08-14
CN1398185A (zh) 2003-02-19
CA2398840A1 (en) 2001-08-16
EE200200440A (et) 2003-12-15
KR20020089345A (ko) 2002-11-29
NZ521061A (en) 2005-01-28
BR0108283A (pt) 2002-10-29
HK1049967A1 (zh) 2003-06-06
JP2003524645A (ja) 2003-08-19
EP1267889A1 (en) 2003-01-02
WO2001058455A1 (en) 2001-08-16
AU3022901A (en) 2001-08-20

Similar Documents

Publication Publication Date Title
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20031270L (no) Imidazolderivater som Raf-kinaseinhibitorer
ATE387450T1 (de) Meso-substituierte porphyrine
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
IS7648A (is) Dífenýlasetídínónafleiður til að meðhöndla fituefnaskiptasjúkdóma
ZA200700481B (en) N-(1-(1-beznyl-4-pheynl-1H-imidazol-2-yl)-2,2-dymenthylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
WO2004056827A3 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2009156735A3 (en) New therapeutic agents
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
GB0222514D0 (en) Organic compounds
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
EA200200848A1 (ru) Способ потенцирования терапевтической эффективности таксана и его производных
BR0214020A (pt) Método para tratar fibrose cìstica
WO2003076445A3 (en) Microtubule stabilizing compounds
AU2003241661A1 (en) Photosensitizer for generating singlet oxygen and method for generating singlet oxygen
EA200701072A1 (ru) Препараты бензотиазола и их применение
CL2004001038A1 (es) Procedimiento para sintetizar compuestos biciclicos condensados con una unidad pirazolo-2-carboxialdehido; y los compuestos intermediarios que se usan.
AU2003220338A1 (en) Photosensitizers for photodynamic therapy of microbial infections
AU2629500A (en) A method for treating patients with acne by administering a cyclic gmp pde inhibitor